Fig. 1From: High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivoHMGB1 is upregulated in HepG2 cells following sorafenib treatment (*p < 0.05). HepG2 cells were treated with 5 μM sorafenib (Sor) or DMSO, and the HMGB1 expression was measured by (a) qPCR and (b) western blottingBack to article page